These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 35582527)
1. Drug resistance and minimal residual disease in multiple myeloma. Gozzetti A; Ciofini S; Sicuranza A; Pacelli P; Raspadori D; Cencini E; Tocci D; Bocchia M Cancer Drug Resist; 2022; 5(1):171-183. PubMed ID: 35582527 [TBL] [Abstract][Full Text] [Related]
2. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. Mina R; Oliva S; Boccadoro M J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32645952 [TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy. Ferla V; Antonini E; Perini T; Farina F; Masottini S; Malato S; Marktel S; Lupo Stanghellini MT; Tresoldi C; Ciceri F; Marcatti M Front Oncol; 2022; 12():932852. PubMed ID: 36052251 [TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry. Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567 [TBL] [Abstract][Full Text] [Related]
6. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Mohan M; Kendrick S; Szabo A; Yarlagadda N; Atwal D; Pandey Y; Roy A; Parikh R; Lopez J; Thanendrarajan S; Schinke C; Alapat D; Sawyer J; Tian E; Tricot G; van Rhee F; Zangari M Blood Adv; 2022 Feb; 6(3):808-817. PubMed ID: 34807986 [TBL] [Abstract][Full Text] [Related]
7. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422 [TBL] [Abstract][Full Text] [Related]
8. MRD Assessment in Multiple Myeloma: Progress and Challenges. Bertamini L; D'Agostino M; Gay F Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030 [TBL] [Abstract][Full Text] [Related]
10. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. Waldschmidt JM; Anand P; Knoechel B; Lohr JG Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150 [TBL] [Abstract][Full Text] [Related]
12. Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma. Oliva S; D'Agostino M; Boccadoro M; Larocca A Front Oncol; 2020; 10():1. PubMed ID: 32076595 [TBL] [Abstract][Full Text] [Related]
13. What to do with minimal residual disease testing in myeloma. Manasanch EE Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal genetically detectable minimal residual disease by fluorescence Cui J; Yu T; Lv R; Liu J; Fan H; Yan W; Xu J; Du C; Deng S; Sui W; Ho M; Xu Y; Anderson KC; Dong X; Qiu L; An G Ther Adv Med Oncol; 2024; 16():17588359231221340. PubMed ID: 38249329 [TBL] [Abstract][Full Text] [Related]
15. Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real-world practice. McMillan A; Tran TA; Galas-Filipowicz D; Camilleri M; Lecat C; Ainley L; Guo Y; Yong K; Sive J Cytometry B Clin Cytom; 2023 Jul; 104(4):304-310. PubMed ID: 36370149 [TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F EClinicalMedicine; 2023 Jun; 60():102016. PubMed ID: 37396800 [TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall AC; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS Lancet Haematol; 2023 Nov; 10(11):e890-e901. PubMed ID: 37776872 [TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma. Kim HY; Yoo IY; Lim DJ; Kim HJ; Kim SH; Yoon SE; Kim SJ; Cho D; Kim K Ann Lab Med; 2022 Sep; 42(5):558-565. PubMed ID: 35470273 [TBL] [Abstract][Full Text] [Related]
19. Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity. Suzuki K; Nishiwaki K; Yano S Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638353 [TBL] [Abstract][Full Text] [Related]
20. [Prognostic significance of sequencing-based MRD detection in multiple myeloma]. Takamatsu H Rinsho Ketsueki; 2015 Aug; 56(8):989-96. PubMed ID: 26345557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]